UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres <u>ROBINS HA</u>	ss of Reporting Person RLAN S	n*	2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT]		tionship of Reporting Pers all applicable) Director Officer (give title	10% Owner Other (specify		
(Last) C/O ADAPTIVI SUITE 200	ADAPTIVE BIOTECHNOLOGIES CORP.		3. Date of Earliest Transaction (Month/Day/Year) 01/19/2021		below) Chief Scientific	below) Officer		
(Street) SEATTLE (City)	WA (State)	98102 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year) 01/21/2021	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code V		Amount	(A) or (D) Price		Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	01/19/2021		M ⁽¹⁾		50,000	A	\$6.55	50,679	D	
Common Stock	01/19/2021		S ⁽¹⁾		31,146	D	\$ 67.02 ⁽²⁾	19,533	D	
Common Stock	01/19/2021		S ⁽¹⁾		3,001	D	\$ 67.74 ⁽³⁾	16,532	D	
Common Stock	01/19/2021		S ⁽¹⁾		5,701	D	\$69.26 ⁽⁴⁾	10,831	D	
Common Stock	01/19/2021		S ⁽¹⁾		8,052	D	\$ 69.97 ⁽⁵⁾	2,779	D	
Common Stock	01/19/2021		S ⁽¹⁾		2,100	D	\$70.75 ⁽⁶⁾	679	D	
Common Stock	01/20/2021		M ⁽¹⁾		50,000	A	\$6.55	50,679	D	
Common Stock	01/20/2021		S ⁽¹⁾		20,394	D	\$66.84 ⁽⁷⁾	30,285	D	
Common Stock	01/20/2021		S ⁽¹⁾		24,945	D	\$67.39 ⁽⁸⁾	5,340	D	
Common Stock	01/20/2021		S ⁽¹⁾		4,661	D	\$68.2 ⁽⁹⁾	679	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(3),,,,														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (saction e (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$6.55	01/19/2021		M ⁽¹⁾			50,000	(10)	02/07/2028	Common Stock	50,000	\$0.00	350,000	D	
Stock Option (Right to Buy)	\$6.55	01/20/2021		M ⁽¹⁾			50,000	(10)	02/07/2028	Common Stock	50,000	\$0.00	300,000	D	

Explanation of Responses:

1. These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$66.39 to 67.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$67.42 to 68.20, inclusive.

4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$68.54 to 69.53, inclusive.

5. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$69.54 to 70.50, inclusive.

6. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$70.54 to 71.02, inclusive.

7. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$66.07 to 67.06, inclusive.

8. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$67.07 to 68.06, inclusive.

9. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$68.07 to 68.48, inclusive.

10. The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

<u>/s/ Harlan Robins by Eric</u> <u>Billings, Attorney-in-Fact</u>



** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.